Pharmaceuticals
Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19
-- ASC11 is an in-house discovered oral small molecule drug candidate, targeting 3-chymotrypsin like protease (3CLpro) -- In antiviral cellular assays with infectious SARS-CoV-2, ASC11 demonstrated higher potency against SARS-CoV-2 than other 3CLpro inhibitors including Nirmatrelvir, S-217622, P...
2022-11-02 08:10
3709
SK pharmteco appoints Joerg Ahlgrimm as CEO to spearhead the next phase of company growth and innovation
- Joerg Ahlgrimm brings 25 years of expertise in pharmaceuticals and innovative cell and gene therapies - SK pharmteco expands pharmaceutical drug production and advances cell and gene therapy production - Annual sales expected to exceed KRW 1 trillion in 2022 FRANKFURT, Germany, Nov. 2, 2022 /PR...
2022-11-02 02:00
2861
Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Receives NMPA Approval for the Treatment of sqNSCLC
SHANGHAI, Nov. 1, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696. HK) announced that its first self-developed innovative anti-PD-1 monoclonal antibody (mAb) HANSIZHUANG (generic name: serplulimab injection), in combination with carboplatin and albumin-bound paclitaxel for the first-lin...
2022-11-01 21:32
5040
Hummingbird Bioscience to Attend the Credit Suisse 31st Annual Healthcare Conference
SAN FRANCISCO, HOUSTON and SINGAPORE, Nov. 1, 2022 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced that Chief Financial OfficerJosh House and Chief Deve...
2022-11-01 20:00
2134
Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis
NEWTON, Mass. and FLORENCE, Italy, Nov. 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, today anno...
2022-11-01 19:40
3425
Citeline and Norstella Complete Merger to Form a $5 Billion Global Pharmaceutical Technology Company
With more than 1,600 employees across the globe, the new organization is now one of the world's largest pharma intelligence solutions providers on the market YARDLEY, Pa., Nov. 1, 2022 /PRNewswire/ -- Norstella, a global leader with end-to-end solutions that smooth access to life-saving therapies...
2022-11-01 19:00
5073
Pervistop®, the once-daily supplement specifically designed to manage persistent HPV, is now available for exclusive distribution rights worldwide.
Lo.Li. Pharma International to unveil an innovative new product at CPHI Frankfurt, which has already gained the interest of numerous distribution partners. Pervistop® promises to be an extremely effective tool in the management of an exceedingly unpredictable disease. FRANKFURT, Germany, Nov. 1,...
2022-11-01 16:00
3930
Gerresheimer AG and Stevanato Group present EZ-fill Smart™, a new and innovative Ready-To-Fill Vial Platform
DÜSSELDORF, Germany and PIOMBINO DESE, Italy, Nov. 1, 2022 /PRNewswire/ -- Gerresheimer AG, a leading global provider of healthcare & beauty and drug delivery systems for pharma, biotech and cosmetics and Stevanato Group S.p.A., a global provider of drug containment, drug delivery and diagnostic ...
2022-11-01 15:00
2039
RemeGen Releases Phase II Clinical Study Data for Treatment of Myasthenia Gravis in Chinese Patients
YANTAI, China, Nov.1, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, recently released data from the Phase II clinical study of its proprietary novel fusion protein Telitacicept for the treatment of myasthenia ...
2022-11-01 12:12
3632
Codex Genetics to Offer Guardant Health's Precision Oncology Tests in Hong Kong and Macau
HONG KONG, Nov. 1, 2022 /PRNewswire/ -- Codex Genetics today announced an exclusive collaboration with Guardant Health Asia,Middle East and Africa (AMEA) to offer comprehensive genomic profiling (CGP) tests to hospitals and clinics in Hong Kong and Macau. As part of the collaboration, Gua...
2022-11-01 11:21
4678
Antengene Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors
* ATG-017 is a small molecule ERK1/2 inhibitor and Antengene has obtained exclusive global rights to develop, commercialize and manufacture ATG-017. * IND clearance enables Antengene to initiate the combination portion of the Phase I "ERASER" clinical trial inthe United States (U.S.) to evalua...
2022-10-31 20:22
3679
Xinhua Silk Road: Cloud + offline fair injects new vitality into National TCM Materials & Pharmaceuticals Trade Fair
BEIJING, Oct. 31, 2022 /PRNewswire/ -- The 53rd National Traditional Chinese Medicine (TCM) Materials and Pharmaceuticals Trade Fair, a vital platform to promote communication in medical field inChina, bore witness to how online-offline integration greatly boosted trading on the opening day on Fr...
2022-10-31 19:00
5665
Innovent Announces First Patient Dosing in Australia in Phase I Study of IBI343 (Recombinant anti-Claudin18.2 Monoclonal Antibody-drug Conjugate) in Patients with Advanced Solid Tumors
ROCKVILLE, Md. and SUZHOU, China, Oct. 30, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmolog...
2022-10-31 08:00
4213
Samyang Holdings' Lafullen Makes Splash in Korean Medical Aesthetics Market
- Successfully demonstrated Lafullen's safety and efficacy at autumn medical symposiums - Shared treatment protocols and clinical cases to lecturers by specialist - Continued to develop evidence-based marketing to Asian markets SEOUL, South Korea, Oct. 31, 2022 /PRNewswire/ -- Samyang Holdings ...
2022-10-31 08:00
4010
World Stroke Organization Tackle Gaps in Access to Quality Stroke Care
GENEVA, Switzerland, Oct. 28, 2022 /PRNewswire/ -- On World Stroke Day (29th
Oct), the World Stroke Organization has announced the launch of a new program
that aims to drive access to quality acute stroke care and save lives around
the world.
2022-10-29 06:01
10619
Hinova Disclosed the Preclinical Results of HP518 (Oral AR PROTAC) at the 5th Annual TPD Summit
BOSTON, Oct. 29, 2022 /PRNewswire/ -- Hinova Pharmaceuticals Inc. (STAR: 688302), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers and metabolic diseases through targeted protein degradation technologies, today presented their preclinical results of ...
2022-10-29 05:30
10083
Pharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under Accelerated Assessment for leniolisib
Marketing authorisation in the European Economic Area anticipated in H1 2023 LEIDEN, Netherlands, Oct. 28, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM / Nasdaq: PHAR) announces today that its Marketing Authorisation Application (MAA) for leni...
2022-10-28 13:00
5821
Acceptance Of The Application For Clinical Trial Of Recbio Novel Adjuvanted Recombinant Quadrivalent HPV Vaccine
TAIZHOU, China, Oct. 28, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that, the Group has recently received a notice of acceptance from the National Medical Products Administration to accept the appli...
2022-10-28 11:10
4940
Sebela Pharmaceuticals® Acquires Exclusive Licensing Rights to Develop and Commercialize Tegoprazan in the U.S. and Canada
Phase 3 Trials Initiated with Tegoprazan for the Treatment of Erosive Esophagitis and Non-erosive Reflux Disease BRAINTREE, Mass., Oct. 28, 2022 /PRNewswire/ -- Sebela Pharmaceuticals® has entered an exclusive partnership with HK inno.N Corporation to license tegoprazan inthe United States and C...
2022-10-28 09:00
4260
Sciwind Biosciences Announces Positive Interim Results from Ongoing Phase 2b Clinical Trial of XW003 (Ecnoglutide) in Patients with Obesity
- Mean body weight loss of 11.1% in participants receiving once-weekly injections of 2.4 mg XW003 for 18 weeks - 88.5% and 57.7% of participants receiving 2.4 mg XW003 for 18 weeks achieved weight loss of≥5% and ≥10%, respectively - XW003 was safe and well tolerated, with an adverse event p...
2022-10-28 08:00
3667
Week's Top Stories
Most Reposted
Futurise Impact Report 2025 Highlights Progress in Regulatory Innovation Future-Ready Technologies
[Picked up by 272 media titles]
2026-09-09 13:26
Hyundai Motor Company Becomes Official Automotive Partner of the UEFA Champions League
[Picked up by 266 media titles]
2026-09-07 13:00
People See One Brand. The Internet May Show Them Hundreds More.
[Picked up by 264 media titles]
2026-09-07 09:00Novo Holdings invests in ForYou Medical to support global growth in advanced wound care manufacturing
[Picked up by 264 media titles]
2026-09-10 15:00Nuix Expands Generative AI for Legal Review, Debuts AI Chat for Case Data
[Picked up by 262 media titles]
2026-09-07 09:40Most Read
AIA Australia, Long Service Corporation, New Zealand Police and RMBL Investments Named 2026 Appian APJ Innovation Award Winners
2026-09-07 11:28
7566
Sungrow Calls for Scenario-based and integrated systems to Accelerate the Next Phase of the Renewable Energy Transition
2026-09-09 22:26
6445
Hyundai Motor Company Becomes Official Automotive Partner of the UEFA Champions League
2026-09-07 13:00
5824